Theranostics Market
Report ID: SQMIG35G2362
Report ID: SQMIG35G2362
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35G2362 |
Region:
Global |
Published Date: January, 2026
Pages:
187
|Tables:
119
|Figures:
72
Global Theranostics Market size was valued at USD 2.5 Billion in 2024 and is poised to grow from USD 2.83 Billion in 2025 to USD 7.81 Billion by 2033, growing at a CAGR of 13.5% during the forecast period (2026–2033).
The global theranostics market share is moving forward with significant momentum due to increased demand for personalized medicine and increased prevalence of chronic diseases such as cancer and cardiovascular disorders. The combination of diagnostic and therapeutic capabilities into a single platform is enhancing treatment effectiveness and cost-savings in healthcare. Further developments in imaging and biomarkers for targeted drug delivery continue to expand theranostic applications in developed and emerging markets.
Nevertheless, the global theranostics market growth possesses certain restraints, despite its attractive growth opportunity. High development costs, complex regulatory hurdles, and lack of awareness in low-income regions continue to create challenges for widespread adoption. Restricted reimbursement and the need for specialized infrastructure also limit the scalability of theranostic solutions in standard clinical practice. Reaching solutions to these barriers through policy incentives, investment to R&D, and strategic alliances will be important for long-term growth in the global theranostics market.
How are AI and Emerging Technologies Reshaping the Global Theranostics Market?
AI and other developing technologies are fundamentally changing the international theranostics market growth, by creating super personalized, accurate, and data-driven healthcare solutions. Artificial intelligence allows more precise tumor profiling, and accelerates imaging workflows, using predictive analytics to real-time data throughout a patient’s course of treatment. By integrating IoT and smart healthcare systems that monitor patient treatment in real time, support the capturing of data, and make any needed adjustments during treatment plans. These combined technologies produce more outcomes with less cost, and expand the opportunities for theranostics solutions in oncology, and chronic disease management.
A current example of this transformation is the introduction of a global initiative that seeks to advance AI-powered precision oncology and theranostics field through their collaborative efforts. The program shall create consistent clinical protocols, build supportive infrastructures and maintain a support system for researchers and their collaborators taking part in international research training, exchanges, and for learning with everyone involved throughout this program. The goal of highlighting AI-driven theranostics in nuclear medicine would support behaviour change, increase real-world evidence, improve AI adoption in clinical practice, and produce similar benefits across other healthcare systems. The program would work towards producing a network of sustainability that was viable in the current or future similar programs.
Market snapshot - 2026-2033
Global Market Size
USD 3.06 billion
Largest Segment
Oncology
Fastest Growth
Neurology
Growth Rate
5.9% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Theranostics Market is segmented by Product, Technology, Disease, End-User and region. Based on Product, the market is segmented into Diagnostic Imaging Agents, Radiopharmaceuticals & Targeted Therapeutics, IVD/Biomarker Screening Kits and Software & Services. Based on Technology, the market is segmented into Molecular Imaging (PET/SPECT), Radioligand Therapy, Nanoparticle-based Theranostics and Biomarker-driven Companion Diagnostics. Based on Disease, the market is segmented into Oncology, Neurology, Cardiovascular Diseases, Immunological/Inflammatory Disorders and Others. Based on End-User, the market is segmented into Hospitals & Cancer Treatment Centres, Diagnostic Laboratories, Research & Academic Institutes and Theranostics Centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The oncology segment is the leader in the global theranostics market outlook, mainly because of the increase in the global cancer burden and the growing use of personalized cancer therapy. The synergism of imaging and therapy, particularly in radio theranostics, has increased the accuracy and effectiveness of oncology care, and the continued growth of investments in cancer research and the ongoing increase in targeted therapies only adds to this dominance.
The biomarkers segment is expected to experience the highest growth because of their expanding role in early disease detection, treatment selection, and therapeutic response monitoring. This expansion is being driven by advances in molecular diagnostics, and the higher demand for minimally invasive procedures. The expanding applications of biomarkers in precision medicine as well as their integration with AI-based platforms also supports expedited growth in this segment.
The global theranostics market forecast is heavily weighted to hospitals due to their required infrastructure, access to integrated diagnostics and intervention technology, and ability to absorb higher patient volumes. Hospital interaction with complex disease management has prompted the use of theranostics products as primary users, especially in oncology and cardiovascular disease. Clinical and research partnerships, with pharmaceutical companies and research partners, also contributed to market expansion through applications of precision medicine by hospitals.
On the whole, genomics is emerging as the new segment of the theranostics market revenue and likely represents the fastest growing segment of the theranostics market that is delivering personalized medicine options. With next generation sequencing (NGS) taking the lead and costs associated with sequencing the entirety of the human genome decreasing, the availability of genomics in clinical practice has expanded. Genomics enables a means of better stratifying disease and of making better intervention choices for patients with inherited conditions and rare diseases. Finally, advancement in funding research and expanding awareness around genetic testing is assisting in the rapid expansion of genomics in this segment.
To get detailed segments analysis, Request a Free Sample Report
Currently, due to beneficial institutional support developed in health care, strong collaboration between academia and private industry, high rates of chronic diseases like cancer, and strong early adoption of advance medical technologies in North America, the region currently leads the theranostics market regional outlook. North America is characterized as having excellent and speedy reimbursement models, having a solid value proposition from its investment in contributed annual rationalization for personalized medicine and theranostics through academic centers, and an established ecosystem that has catered to theranostics development for over a decade and continues to strengthen to this day.
Due to the expanded focus on precision medicine in the United States we are seeing a greater number of strategic partnerships (SP) with leading hospitals, universities, and medicine systems, existing and emerging theranostic innovation is increasingly focusing on collaborations with therapeutic companies to manufacture theranostics applications, like hematology cancer therapies and the management of chronic illness through diagnostic and imaging integration platforms.
Canada emerges as a strong force in the theranostics market regional forecast, propelled by government investment in personalized medicine and because of increasing investment in research and clinical trials. Health institutions are increasingly instituting integrated diagnostic-therapeutic models to improve patient outcomes for cancer and other chronic health conditions.
The Asia-Pacific region is growing the fastest in the theranostics market revenue, fueled by substantial healthcare modernization, increasing awareness of personalized medicine, and growing patient populations with unmet clinical needs. Many countries have infrastructure to update diagnostic operations and partnerships to acquire the latest technologies. Government policies generally encourage investment in genomics and molecular diagnostics to spur further growth in their region.
Japan is distinguishing itself among the competing countries in the theranostics market strategies, mechanism by expressly allowing promotion of Precision Healthcare and Innovation. The government funding programs for converting academic research into clinical practice are one notable example of this. There is an increasing integration of genomic testing and theranostic platforms into standard cancer treatment algorithms.
South Korea continues to develop new regulation mechanisms related to healthcare, so patients have quicker access to new therapeutic for rare and chronic diseases. South Korea is actively creating new mechanisms for which patients have access to innovative new therapies and financial endavors into pursuing cell and gene therapy and other innovative next generation technology theranostics growing region.
Europe has a strong place in the theranostics industry trends, which is driven by a well-structured health care system, good coordination of research networks, and willingness to engage in translational medicine. Each country is making great strides in promoting public-private partnerships, regulatory innovation, and cross-border clinical cooperation, helping to pave the way for theranostic adoption.
Germany offers an important contribution to the European market, with a solid biomedical research base and increased implementation of theranostic tool development in hospitals, particularly around oncology. The ability to leverage advanced sequencing technology with advancements in molecular diagnostics is helping to develop greater accuracy in treatments and better patient outcomes.
France is trying to push the precision medicine paradigm through national healthcare actions, which are concentrated on personal paths of treatment lies in its support for the incorporation of diagnostic imaging with targeted therapies, post-hoc prognosis, with a special emphasis on oncology and neurology.
The United Kingdom is fostering theranostics approaches for clinicians through research programs supported by the government, and partnerships with academics, biotech companies, and healthcare providers. The recent push to support early detection and targeted therapies has the potential to make the UK the leading international innovation hub for clinical theranostics.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growing Demand for Personalized Medicine
Advances in Molecular Imaging and Biomarker Discovery
High Cost of Theranostic Development and Implementation
Multiple Regulatory and Approval Pathways
Request Free Customization of this report to help us to meet your business objectives.
The global theranostics market strategies for the most part, consolidated yet competitive as players try to expand geographic presence, product pipeline diversification, and technological advancements. Players are investing resources into the development of radiopharmaceuticals, next-gen imaging, and AI-enabled diagnostics to enhance their offering. Collaborations between commercial partners and academic institutions have been responsible for the innovations that have shortened time-to-market. Companies look at in-region manufacturing and distribution, to maintain local regulatory compliance and reduce distribution time.
In a competitive sense, the introduction of radioligand therapies with companion diagnostics is directed to non-randomized studies that advance precision of treatment in oncology. This has gained traction, despite competition in some of the new authorized studies and commercialization that management in larger companies want. The range of the market is increasing, as startups, and midcapacity enterprises have begun disrupting the market by introducing products leveraging innovations with evidence-based studies apropos of liquid biopsy, genomics, and diagnostics, many have venture capital funding associated with an academic institution. These actors are creating niches in the market that target cost effective, and minimally intrusive solutions pertaining to personalized care models.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the theranostics market is growing quickly as a result of recent developments in radioligand therapies, regulatory approvals, and new clinical pipelines. Oncology is still the predominant application segment, with emerging integrated diagnostic and therapeutic applications leading to the charge. North America is currently the leading global market with a strong research ecosystem and supportive regulatory authorities. One of the main factors propelling the growth of theranostics is the increasing development of personalized medicine. With AI-enhanced diagnostic tools and precise medication delivery, the demand for these alternatives is driving many research and commercial opportunities. Another continuing constraint on broader adoption is the cost of the development and commercialization of theranostic agents. Nevertheless, ongoing investment in biomarker discovery research and molecular imaging technology delivers real-time, targeted treatment; which continues to frame theranostics in the overall shift toward individualized, outcome-based healthcare.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.5 Billion |
| Market size value in 2033 | USD 7.81 Billion |
| Growth Rate | 13.5% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
Top Player’s Company Profiles
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Theranostics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Theranostics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Theranostics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Theranostics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
